Fluoroquinolone Toxicity: A Physician’s Perspective

What Are the Symptoms of Fluoroquinolone Toxicity?

There is no single presentation of fluoroquinolone toxicity. Some patients primarily experience tendon and musculoskeletal problems. Others develop neurological or systemic symptoms. Some develop symptoms across multiple systems at the same time.

Nervous System Symptoms

Neurological symptoms can be among the most frightening aspects of fluoroquinolone toxicity. Patients may experience:

• Burning or tingling
• Peripheral neuropathy
• Insomnia
• Anxiety
• Panic
• Brain fog
• Cognitive changes
• Tremors
• Mood changes

Tendon and Musculoskeletal Symptoms

Fluoroquinolones have also been associated with tendon and connective tissue injury. Symptoms may include:

• Tendon pain
• Joint instability
• Musculoskeletal pain
• Tendon rupture

The Achilles tendon is one of the structures commonly associated with fluoroquinolone-related tendon injury.

Systemic Symptoms

Some patients experience symptoms that extend beyond one body system, including:

• Chronic fatigue
• Exercise intolerance
• Muscle weakness
• Heart palpitations
• Digestive issues
• Widespread systemic symptoms

What Causes Fluoroquinolone Toxicity?

There does not appear to be one single mechanism that explains every case of fluoroquinolone toxicity. Researchers have investigated several potential mechanisms, including mitochondrial dysfunction, oxidative stress, connective tissue injury, and effects on the nervous system.

Mitochondrial Dysfunction and Oxidative Stress

One of the mechanisms I pay particular attention to is mitochondrial dysfunction. Mitochondria are responsible for producing cellular energy. Fluoroquinolones have been studied for their potential effects on mitochondrial function and oxidative stress. Recent laboratory research found effects involving complexes I and IV of the mitochondrial electron transport chain, two parts of the system mitochondria use to generate cellular energy. When normal energy production becomes disrupted, the consequences can extend well beyond one area, contributing to the systemic effects described above. This is one reason I don’t view severe fluoroquinolone toxicity as simply tendon pain or an isolated medication side effect. In some patients, multiple systems appear to be affected simultaneously.

Tendon and Connective Tissue Effects

Fluoroquinolones have been associated with tendon and connective tissue injury, which may help explain the tendon and musculoskeletal effects described above. Research into fluoroquinolone-associated tendinopathy has identified changes involving tendon cells, type I collagen metabolism (a major structural component of tendons), and oxidative stress, although no single mechanism explains every injury. Connective tissue is widespread throughout the body, so an adverse reaction involving these structures may not remain confined to one tendon or joint.

Nervous System Effects

Fluoroquinolones are known to cross into the central nervous system, and researchers have examined their effects on neurotransmitter activity, including GABA-related pathways. GABA is one of the brain’s main inhibitory neurotransmitters, helping reduce neuronal activity and regulate functions such as sleep and anxiety. Some research suggests certain fluoroquinolones may interfere with GABA-A receptor signaling. The nervous system influences nearly every organ system, which may help explain why these effects can occur as part of a broader multisystem reaction rather than in isolation. Patients I’ve treated often describe these neurological effects showing up alongside tendon, muscular, and systemic problems rather than as a standalone issue.

Why Do Fluoroquinolone Reactions Vary Between People?

Not every patient who takes a fluoroquinolone develops toxicity. However, some individuals may be more susceptible to severe or prolonged reactions. In my practice, factors I consider when evaluating why reactions vary include:

• Previous fluoroquinolone exposure
• Concurrent corticosteroid use
• Concurrent NSAID use
• Other medications being taken at the same time
• Individual differences in drug metabolism
• Underlying connective tissue vulnerability
• Oxidative stress or mitochondrial dysfunction
• High physical stress or overtraining
• Genetic differences in detoxification and antioxidant pathways

I also pay close attention to the circumstances surrounding the exposure. How many previous courses of fluoroquinolones has the patient taken? What other medications were being used? What was their health like beforehand? Were they exercising heavily during or after the prescription? Did subtle symptoms occur after an earlier course before a more severe reaction developed? The answer is likely more complicated than the dose alone. Drug exposure, previous exposures, individual susceptibility, medication combinations, physical stress, and other patient-specific factors may all influence how someone responds.

The Cumulative Effect: Dr. Ghalili’s Jenga Analogy

I use the Jenga analogy to help patients understand how cumulative exposure and other stressors may contribute to fluoroquinolone toxicity progression. Imagine the body’s cellular resilience as a Jenga tower. Each exposure or additional stressor may remove another piece of that resilience. Initially, the tower can remain stable despite some missing pieces. One exposure or stressor may remove a block, but the tower remains standing. Another removes another block, and you may still feel relatively normal. Then another course or contributing stressor removes a critical block, and suddenly the tower falls. This is how I think about patients who tell me: “I’ve taken Cipro before and I was fine. Why did this happen to me this time?” Previous exposure can matter more than people realize. Some patients may take one course or even several courses before experiencing a severe reaction. I believe there can be a cumulative component in susceptible patients, where repeated exposures and other stressors eventually push the body beyond a threshold.

Why Does One Person Get Tendon Problems While Another Gets Neurological Symptoms?

There is no single presentation of fluoroquinolone toxicity. Some patients primarily experience tendon and musculoskeletal problems. Others develop neuropathy, burning sensations, insomnia, anxiety, cognitive problems, or other neurological symptoms. Some develop symptoms across multiple systems. In my clinical experience, the pattern may be influenced by the patient’s previous health, concurrent medications, previous exposures, physical activity, and individual susceptibility. For example, a patient who continues intense physical activity while a tendon is vulnerable may place additional stress on the Achilles tendon or another affected structure. This doesn’t mean exercise caused the toxicity. It means the same medication exposure may manifest differently depending on the patient and what was happening in their body at the time.

When Can Symptoms Start, Change, or Worsen?

Fluoroquinolone toxicity does not always follow a predictable timeline. Some patients notice symptoms during the course of the antibiotic. Others experience a delayed reaction that develops days or even weeks after stopping the medication. Patients understandably ask: “If the antibiotic is out of my system, why am I still getting worse?” The presence of a medication in the bloodstream and the biological effects associated with an adverse drug reaction are not necessarily the same thing. If fluoroquinolone exposure has already contributed to mitochondrial dysfunction, oxidative stress, nerve injury, or connective tissue damage, symptoms may continue after the medication itself has been discontinued. Physical activity can become particularly important when tendons and connective tissues are involved. Some patients continue running, lifting weights, playing sports, or exercising because they do not yet realize their tissues may be vulnerable. Additional mechanical stress on an already affected tendon may contribute to worsening symptoms or injury. Symptoms may also fluctuate or shift over time. Some patients notice periods of improvement followed by sudden “crashes” or flare-ups triggered by stress, illness, overexertion, repeat antibiotic exposure, steroids, or poor sleep. This unpredictability is one reason fluoroquinolone toxicity is frequently misunderstood. Symptoms often do not follow the pattern of a typical injury or illness.

How Is Fluoroquinolone Toxicity Diagnosed?

There is no single test that can definitively diagnose fluoroquinolone toxicity. In most cases, diagnosis is based on a careful review of medical history, particularly prior exposure to fluoroquinolone antibiotics, along with the pattern and timing of symptoms. This is also one reason fluoroquinolone toxicity is often missed. Many patients do not look obviously ill from the outside. Standard lab work may not fully explain what they are feeling, and imaging may not capture the full extent of the dysfunction.

Why Standard Tests May Be Normal

Most routine bloodwork and imaging studies are not designed to detect mitochondrial dysfunction, oxidative stress, subtle nerve injury, or widespread connective tissue dysfunction. I explain this to patients using the example of two cotton sheets. Imagine one sheet with extremely dense, strong fibers and another that has lost a significant amount of its structural strength. From across the room, they both still look like sheets. But when you place stress on them, they may behave very differently. The same general concept can help explain why imaging may not always account for the severity of what a patient is feeling. Routine imaging may not capture every microscopic or functional change occurring within tissue. This is why I do not evaluate suspected fluoroquinolone toxicity based on one MRI or laboratory result. I look at the entire clinical picture: What medication was taken? When was it taken? What symptoms appeared afterward? How did those symptoms progress? Were there previous exposures? What other medications and physical stressors occurred around the same time? The timeline matters. In some cases, additional testing may be used to evaluate broader patterns that could be contributing to symptoms, such as:

• Markers related to inflammation
• Nutrient status and cellular function
• Metabolic or oxidative stress patterns

However, these tests do not confirm fluoroquinolone toxicity on their own. The most important factor is recognizing the clinical pattern and understanding how symptoms developed after antibiotic exposure.

FDA Warnings for Fluoroquinolone Antibiotics

Over the past two decades, the U.S. Food and Drug Administration has issued multiple safety warnings regarding fluoroquinolone antibiotics, reflecting growing concerns about their potential for serious and sometimes long-lasting side effects. Key FDA updates include:

• 2008: A boxed warning was added for increased risk of tendonitis and tendon rupture.
• 2013: Additional warnings highlighted the risk of potentially irreversible peripheral neuropathy.
• 2016: The FDA advised that for certain uncomplicated infections, the risks of fluoroquinolones may outweigh the benefits when other treatment options are available.
• 2018: Expanded warnings included mental health side effects and blood sugar disturbances.
• 2018: The FDA also warned about a rare risk of aortic aneurysm or dissection in certain higher-risk patients.

In its 2016 safety communication, the FDA specifically recommended reserving fluoroquinolones for patients who do not have alternative treatment options for conditions such as:

• Acute bacterial sinusitis
• Acute exacerbation of chronic bronchitis
• Uncomplicated urinary tract infections

The agency concluded that for these common conditions, the potential risks may outweigh the expected benefits in certain cases.

Which Drugs Are Fluoroquinolones?

Fluoroquinolones are a class of antibiotics that include both generic and brand-name formulations:

• Oral fluoroquinolones: Ciprofloxacin (Cipro, Cipro XR), Levofloxacin (Levaquin), Moxifloxacin (Avelox), Ofloxacin (Floxin), Norfloxacin (Noroxin), Gemifloxacin (Factive), Delafloxacin (Baxdela)
• Injectable fluoroquinolones: Ciprofloxacin IV, Levofloxacin IV, Moxifloxacin IV
• Topical fluoroquinolones (eye/ear drops): Ciprofloxacin (Ciloxan), Ofloxacin (Ocuflox, Floxin Otic), Levofloxacin (Quixin, Iquix)

Topical fluoroquinolones are also available as eye and ear drops. The FDA warnings discussed above about disabling and potentially permanent multisystem side effects apply specifically to systemic fluoroquinolones taken by mouth or injection.